Src Kinases in Tumor Therapy;Src-Kinasen in der Tumortherapie

Medizinische Klinik

Volumn 105, Issue 10, 2010, Pages 711-715

  Dempke, Wolfram ^a   Zippel, Roland ^b  

^a Klinik für Innere Medizin II Hämato Onkologie Gastroenterologie   (Germany)

^b Klinik fur Chirurgie   (Germany)

Author keywords

Clinical trials; Inhibitors; Molecular biology; Src kinases

Indexed keywords

4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; ANTINEOPLASTIC AGENT; BOSUTINIB; DASATINIB; KX 01; N (5 CHLORO 1,3 BENZODIOXOL 4 YL) 7 [2 (4 METHYL 1 PIPERAZINYL)ETHOXY] 5 (TETRAHYDRO 2H PYRAN 4 YLOXY) 4 QUINAZOLINAMINE; PROTEIN TYROSINE KINASE; SARACATANIB; UNCLASSIFIED DRUG; XL 228; XL 999;

CANCER GROWTH; CANCER THERAPY; CARCINOGENESIS; DRUG TOLERABILITY; HUMAN; MOLECULARLY TARGETED THERAPY; PROTEIN FUNCTION; REVIEW;

ANILINE COMPOUNDS; BENZODIOXOLES; CELL PHYSIOLOGICAL PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS, PHASE II AS TOPIC; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; HUMANS; NEOPLASMS; NITRILES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; QUINAZOLINES; QUINOLINES; SRC-FAMILY KINASES; THIAZOLES;

EID: 78649358369     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00063-010-1123-y     Document Type: Review

References (23)

1. Brown MT, Cooper JA. Regulation, substrates and functions of src. Biochim Biophys Acta 1996;1287:121-49.
2. Parson SJ, Parson JT. Src family kinases, key regulations of signal transduction. Oncogene 2004;23:7906-9.
3. Cance WG, Craven RJ, Bergman M, et al. Rak, a novel nuclear tyrosine kinase expressed in epithelial cells. Cell Growth Differ 1994;5:1347-55.
4. Lee J, Wang Z, Luoh SM, et al. Cloning of FRK, a novel human intracellular src-like tyrosine kinase-encoding gene. Gene 1994;138:247-51.
5. Martin GS. The hunting of src. Nat Rev Mol Cell Biol 2001;2:467-75.
6. Fizazi K. The role of src in prostate cancer. Ann Oncol 2007;18:1765-73.
7. Cohn GB, Ren R, Baltimore D. Modular binding domains in signal transduction proteins. Cell 1995;80:237-48.
8. Cooper JA, Gould KL, Cartwirght CA, et al. Tyr527 is phosphorylated in pp60c-src: implications for regulation. Science 1986;231:1431-4.
9. Okada M, Nakagawa H. A protein tyrosine kinase involved in regulation of pp60c-src function. J Biol Chem 1989;264:2086-93.
10. Nada S, Okada M, MacAuley A, et al. Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature 1991;351:69-72.
11. Wheeler DL, Iida M, Dunn EF. The role of src in solid tumors. Oncologist 2009;14:667-78.
12. Biscardi JS, Ishizawar RC, Silva CM, et al. Tyrosine kinase signaling in breast cancer: epidermal growth factor receptor and c-src interactions in breast cancer. Breast Cancer Res 2000;2:203-10.
13. Irby RB, Mao W, Coppola D, et al. Activating src mutation in a subset of advanced human colon cancers. Nat Genet 1999;21:187-90.
14. Laghi L, Bianchi P, Orbetegli O, et al. Lack of mutations at codon 531 of src in advanced colorectal cancers from Italian patients. Br J Cancer 2001;84:196-8.
15. Ishizawar R, Parsons SJ. C-src and cooperating partners in human cancer. Cancer Cell 2004;6:209-14.
16. Hecker TP, Grammer JR, Gillespie GY, et al. Focal adhesion kinase enhances signaling through the Shc/extracellular signal-regulated kinase pathway in anaplastic astrocytoma tumor biopsy samples. Cancer Res 2002;62:2699-707.
17. Aguilera DG, Tsimberidou AM. Dasatinib in chronic myeloid leukemia: a review. Ther Clin Risk Manag 2009;2:281-9.
18. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and drug-interaction study of dasatinib in patients with advanced solid tumors. Cancer 2010;116:1582-91.
19. Lu Y, Li X, Liang K, et al. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab. Cancer Res 2007;67:8240-7.
20. Keller G, Schafhausen P, Brümmendorf TH. Bosutinib. Recent Results Cancer Res 2010;184:199-214.
21. Lara PN, Longmate J, Evans CP, et al. A phase II trial of the src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer. A California Cancer Consortium study. Anticancer Res 2009;20:179-84.
22. Bu Y, Gao L, Smolinski M, et al. KX01 (KX2-391), a src-family kinase inhibitor targeting the peptide-binding domain, suppresses oncogenic proliferation in vitro and in vivo. Proc Am Assoc Cancer Res 2008;2008:4983.
23. Linke R, Dempke W. Management of imatinib-resistant CML patients. Onkologie 2007;30:574-80.